title: Cost-effectiveness of oral anticoagulants versus aspirin in patients after infrainguinal bypass grafting surgery.
abstract: OBJECTIVE
  Several antithrombotic therapies are available for the treatment of patients with peripheral vascular diseases. It is unknown how quality of life and costs of treatment are influenced by different therapies. This study assessed the cost-effectiveness of oral anticoagulants versus aspirin in patients after infrainguinal bypass grafting surgery.
  
  
  METHODS
  Clinical outcome events and event-free survival were collected from 2650 patients in 77 centers who participated in the Dutch Bypass Oral anticoagulants or Aspirin trial. Approximately half the patients had critical ischemia; 60% received vein grafts, and 20% had femorocrural bypass grafts. A model that was primarily driven by clinical outcome events was used as a means of determining quality of life (EuroQol EQ-5D) and costs for each patient. The main outcome measure was the incremental health care costs in relation to the additional number of quality-adjusted life years and the additional number of event-free years.
  
  
  RESULTS
  The mean costs during the 21 months of follow-up were epsilon 6875 per patient in the oral anticoagulants group versus epsilon 7072 in the aspirin group (difference, 197; 95% CI, -746 to 343). The event-free survival was 1.10 years in the group treated with oral anticoagulants versus 1.09 years in the group treated with aspirin (difference, 0.01; 95% CI, -0.07 to 0.08), whereas the corresponding quality-adjusted life years were 1.06 and 1.05, respectively (difference, 0.01; 95% CI, -0.03 to 0.06).
  
  
  CONCLUSIONS
  Health care costs, event-free survival, and quality-adjusted life years in patients after infrainguinal bypass surgery were not different in patients treated with aspirin and patients treated with oral anticoagulants. The extra costs of monitoring patients treated with oral anticoagulants were limited and play no role in the decision for treatment.
authors.affiliation: Institute for Medical Technology Assessment, Erasmus University; the BOA Trial Office, Julius Center for Patient-Oriented Research, and the Department of Vascular Surgery, University Hospital; and the Department of Vascular Surgery, Hospital Amstelveen.
authors.forename: J B
authors.initials: JB
authors.lastname: Oostenbrink
authors.forename: M J
authors.initials: MJ
authors.lastname: Tangelder
authors.forename: J J
authors.initials: JJ
authors.lastname: Busschbach
authors.forename: B A
authors.initials: BA
authors.lastname: van Hout
authors.forename: E
authors.initials: E
authors.lastname: Buskens
authors.forename: A
authors.initials: A
authors.lastname: Algra
authors.forename: J A
authors.initials: JA
authors.lastname: Lawson
authors.forename: B C
authors.initials: BC
authors.lastname: Eikelboom
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage* / Q000191:economics*; D001241:Aspirin / Q000008:administration & dosage* / Q000191:economics*; D003362:Cost-Benefit Analysis; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006801:Humans; D007866:Leg / Q000098:blood supply / Q000601:surgery; D008297:Male; D011183:Postoperative Complications / Q000517:prevention & control*; D011788:Quality of Life; D016896:Treatment Outcome; D014656:Vascular Surgical Procedures / Q000009:adverse effects*
chemical_list: D000925:Anticoagulants; D005343:Fibrinolytic Agents; D001241:Aspirin